Adherence Monitoring for Substance Abuse Clinical Trials

Information

  • Research Project
  • 8647903
  • ApplicationId
    8647903
  • Core Project Number
    R44DA033712
  • Full Project Number
    2R44DA033712-02
  • Serial Number
    033712
  • FOA Number
    PA-13-088
  • Sub Project Id
  • Project Start Date
    8/1/2012 - 12 years ago
  • Project End Date
    8/31/2015 - 9 years ago
  • Program Officer Name
    AKLIN, WILL
  • Budget Start Date
    9/30/2013 - 11 years ago
  • Budget End Date
    8/31/2014 - 10 years ago
  • Fiscal Year
    2013
  • Support Year
    02
  • Suffix
  • Award Notice Date
    9/17/2013 - 11 years ago
Organizations

Adherence Monitoring for Substance Abuse Clinical Trials

DESCRIPTION (provided by applicant): The evaluation and selection of safe and effective pharmacotherapies for drug abuse and addiction, as well as many other diseases and disorders, is performed through clinical trials that rely on patients taking the studied medication at the specified time and frequency. To ensure accurate efficacy measures, adherence to the prescribed regimen must be known. Creare proposes to develop a mobile adherence monitoring system to record timing and dosage information in near-real time during these clinical trials. The Creare system includes confirmatory biomarkers to ensure accuracy of the adherence measures. The system allows for ecological momentary assessments linked to dosing time that provide additional measures of efficacy and drug safety of the test medication over time. During Phase I, we demonstrated the feasibility of our monitoring system by implementing an initial prototype and performing a pilot human subject test to demonstrate feasibility. During Phase II, we will further develop and integrate the hardware and software components of our system, and test the system in the laboratory and in a cohort of subjects on opiate substitution therapy. The Creare team is extremely well qualified to successfully develop and commercialize this system thanks to algorithms, software, and hardware Creare has previously developed for image processing, neuropsychological testing, data sharing, and mobile hearing assessment. Our Clinical Collaborator, Dr. John Mendelson, head of the Addiction and Pharmacology Research Laboratory at the California Pacific Medical Center Research Institute (APRL-CPMCRI), has extensive experience in clinical trials with illicit drug users, and pioneered the methods used in our proposed system.

IC Name
NATIONAL INSTITUTE ON DRUG ABUSE
  • Activity
    R44
  • Administering IC
    DA
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    489973
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    279
  • Ed Inst. Type
  • Funding ICs
    NIDA:489973\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    CREARE, LLC
  • Organization Department
  • Organization DUNS
    072021041
  • Organization City
    HANOVER
  • Organization State
    NH
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    037550071
  • Organization District
    UNITED STATES